Ensysce Biosciences, Inc.

corporate_fare Company Profile

Ensysce Biosciences, Inc.

ENSC·NASDAQ·Life Sciences·CIK 0001716947

Ensysce Biosciences, Inc. is a clinical stage pharmaceutical company focused on developing innovative solutions for severe pain relief. The company aims to reduce the potential for opioid misuse, abuse, and overdose. Ensysce Biosciences is currently developing product candidates designed to improve the safety of prescription drugs. Its primary focus is on opioid pain products and opioid use disorder products. The company was originally incorporated in Delaware in April 2003 as PharmacoFore, Inc., changing its name to Signature Therapeutics Inc. in January 2012. In December 2015, Signature merged with Ensysce Biosciences, Inc. ("Former Ensysce"). In June 2021, Former Ensysce merged with Leisure Acquisition Corporation, which then changed its name to Ensysce Biosciences, Inc. The principal executive office is located at 7946 Ivanhoe Avenue, Suite 201, La Jolla, California 92037.

Ensysce Biosciences, Inc. (NASDAQ:ENSC) is a publicly traded company in the Life Sciences sector. Wiseek monitors ENSC SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

COO Jeffrey Millard Exits Ensysce Biosciences During Strategic Review and Cash Crunch (2026-07-15)
Ensysce Biosciences Registers 1.3M Shares for Resale by Selling Securityholders (2026-06-04)
Ensysce Biosciences Receives Second Nasdaq Delisting Notice for Equity Deficiency (2026-05-22)
Formal Review of Strategic Alternatives Launched by Ensysce Biosciences (2026-05-15)
Cash Falls Sharply as Ensysce Biosciences Reports Widening Q1 Net Loss (2026-05-15)

Financial Snapshot

Fiscal year ended December 31, 2025

Revenue

$5.07M

Net Income

-$10.18M

Diluted EPS

-$3.98

Op. Cash Flow

-$7.81M

Free Cash Flow

-$7.93M

Operating Income

-$10.24M

Cash & Equivalents

$4.31M

Debt / Equity

0.00×

Net Margin

-200.8%

Shares Outstanding

4.57M sh

Source: 10-K · filed 2026-03-30 · accession 0001493152-26-013633

Dilution Risk

Low risk

Filing-implied dilution signals for ENSC, detected from its recent SEC filings · based on capital-structure filings through 2026-05-15.

2 shelf registrations

Going Concern Warning Issued · Cash Balance Plummets

⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with E →

show_chartPrice Chart

Loading chart...

feed ENSC - Latest Insights

Filing Type

Date Range

ENSC

Jul 15, 2026, 4:15 PM EDT

Filing Type: 8-K

Importance Score:

COO Jeffrey Millard Exits Ensysce Biosciences During Strategic Review and Cash Crunch

Price at Filing: $0.2914

Real-time Price: $0.2613

Change: -$0.0301 (-10%)

Market Cap: $4.017M

Sentiment: Negative

View Wiseek Article

ENSC

Jun 04, 2026, 4:42 PM EDT

Filing Type: S-3

Importance Score:

Ensysce Biosciences Registers 1.3M Shares for Resale by Selling Securityholders

Price at Filing: $0.2999

Real-time Price: $0.2613

Change: -$0.0386 (-13%)

Market Cap: $4.017M

Sentiment: Negative

View Wiseek Article

ENSC

May 22, 2026, 4:55 PM EDT

Filing Type: 8-K

Importance Score:

Ensysce Biosciences Receives Second Nasdaq Delisting Notice for Equity Deficiency

Price at Filing: $0.3013

Real-time Price: $0.2613

Change: -$0.040 (-13%)

Market Cap: $4.017M

Sentiment: Negative

View Wiseek Article

ENSC

May 15, 2026, 4:49 PM EDT

Source: Reuters

Importance Score:

Formal Review of Strategic Alternatives Launched by Ensysce Biosciences

Price at Filing: $0.275

Real-time Price: $0.2613

Change: -$0.0137 (-5%)

Market Cap: $4.017M

Sentiment: Neutral

View Wiseek Article

ENSC

May 15, 2026, 4:32 PM EDT

Source: Reuters

Importance Score:

Cash Falls Sharply as Ensysce Biosciences Reports Widening Q1 Net Loss

Price at Filing: $0.278

Real-time Price: $0.2613

Change: -$0.0167 (-6%)

Market Cap: $4.017M

Sentiment: Negative

View Wiseek Article

ENSC

May 15, 2026, 4:20 PM EDT

Filing Type: 10-Q

Importance Score:

Ensysce Biosciences Reports Widening Loss, Critical Cash Shortage, and Highly Dilutive Financing Amidst Going Concern Warning

Price at Filing: $0.275

Real-time Price: $0.2613

Change: -$0.0137 (-5%)

Market Cap: $4.017M

Sentiment: Negative

View Wiseek Article

ENSC

May 15, 2026, 4:20 PM EDT

Filing Type: 8-K

Importance Score:

Ensysce Biosciences Initiates Formal Review of Strategic Alternatives Amid Widened Loss

Price at Filing: $0.275

Real-time Price: $0.2613

Change: -$0.0137 (-5%)

Market Cap: $4.017M

Sentiment: Negative

View Wiseek Article

ENSC

May 12, 2026, 8:00 AM EDT

Source: Access Newswire

Importance Score:

Ensysce Biosciences Secures Taiwan Patent for MPAR® Overdose Protection, Extending IP Through 2042

Price at Filing: $0.329

Real-time Price: $0.2613

Change: -$0.0677 (-21%)

Market Cap: $4.017M

Sentiment: Positive

View Wiseek Article

ENSC

Apr 16, 2026, 8:00 AM EDT

Source: Access Newswire

Importance Score:

Breakthrough Opioid Study Advances: Ensysce Biosciences Gets IRB Nod for Final Phase of PF614-MPAR-102

Price at Filing: $0.5351

Real-time Price: $0.2613

Change: -$0.2738 (-51%)

Market Cap: $4.017M

Sentiment: Positive

View Wiseek Article

ENSC

Apr 08, 2026, 7:29 PM EDT

Filing Type: S-3

Importance Score:

Ensysce Biosciences Registers 20.3M Shares for Resale, Posing Over 200% Potential Dilution Amidst Going Concern Risk

Price at Filing: $0.4889

Real-time Price: $0.2613

Change: -$0.2276 (-47%)

Market Cap: $4.017M

Sentiment: Negative

View Wiseek Article

ENSC

Apr 07, 2026, 9:05 PM EDT

Filing Type: 8-K

Importance Score:

Ensysce Biosciences Secures $2M in Second Tranche Financing, Issuing Convertible Preferred Stock and Warrants

Price at Filing: $0.5552

Real-time Price: $0.2613

Change: -$0.2939 (-53%)

Market Cap: $4.017M

Sentiment: Negative

View Wiseek Article

ENSC

Apr 07, 2026, 8:00 AM EDT

Source: Access Newswire

Importance Score:

Ensysce Biosciences Secures $2M Convertible Preferred Financing, Funds Pain Programs

Price at Filing: $0.5475

Real-time Price: $0.2613

Change: -$0.2862 (-52%)

Market Cap: $4.017M

Sentiment: Neutral

View Wiseek Article

ENSC

Apr 03, 2026, 4:14 PM EDT

Filing Type: 8-K

Importance Score:

Director Curtis Rosebraugh Resigns from Ensysce Biosciences Board

Price at Filing: $0.575

Real-time Price: $0.2613

Change: -$0.3137 (-55%)

Market Cap: $4.017M

Sentiment: Neutral

View Wiseek Article

ENSC

Mar 30, 2026, 4:50 PM EDT

Source: Access Newswire

Importance Score:

Ensysce Biosciences Initiates Pivotal Phase 3 for PF614, Advances MPAR with FDA Breakthrough Therapy Support

Price at Filing: $0.5051

Real-time Price: $0.2613

Change: -$0.2438 (-48%)

Market Cap: $4.017M

Sentiment: Positive

View Wiseek Article

ENSC

Mar 27, 2026, 5:47 PM EDT

Filing Type: 8-K

Importance Score:

Director Resigns Over Disagreement on Substantial Executive Retention Packages

Price at Filing: $0.5275

Real-time Price: $0.2613

Change: -$0.2662 (-50%)

Market Cap: $4.017M

Sentiment: Negative

View Wiseek Article

ENSC

Feb 27, 2026, 4:30 PM EST

Filing Type: 8-K

Importance Score:

Ensysce Biosciences Receives Nasdaq Delisting Notice for Sub-$1.00 Bid Price

Price at Filing: $0.6451

Real-time Price: $0.2613

Change: -$0.3838 (-59%)

Market Cap: $4.017M

Sentiment: Negative

View Wiseek Article

ENSC

Jan 08, 2026, 5:14 PM EST

Filing Type: 8-K

Importance Score:

Ensysce Shareholders Approve Significant Dilution from Financing and Expanded Equity Plan

Price at Filing: $1.06

Real-time Price: $0.2613

Change: -$0.7987 (-75%)

Market Cap: $4.017M

Sentiment: Negative

View Wiseek Article

corporate_fare Company Profile